BIIB

Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will highlight new long-term and real-world evidence, including initial five-year Clarity AD open-label extension data and three-year LEADER data, with new analyses exploring maintenance treatment and at-home subcutaneous administration Presentations across Biogen's Alzheimer's disease portfolio reflect its continued commitment to advancing innovation in Alzheimer's disease, from long-term treatment outcomes and real-world evidence to investigational approaches targeting core disease pathologies, including amyloid and tau CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place November 16–19, 2026, at the Boston Marriott Copley Place in Boston, Massachusetts.

Biogen Inc. ( BIIB ) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - Executive VP & Head of Development Robin Kramer - Executive VP & CFO Alisha Alaimo - President & Head of North America Conference Call Participants Philip Nadeau - TD Cowen, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Michael Yee - UBS Investment Bank, Research Division Alexandria Hammond - Wolfe Research, LLC Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Evan Seigerman - BMO Capital Markets Equity Research Geoffrey Meacham - Citigroup Inc., Research Division David Amsellem - Piper Sandler & Co., Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Lin Tsai - Jefferies LLC, Research Division Marc Goodman - Leerink Partners LLC, Research Division Presentation Operator Good morning. My name is Cynthia, and I will be your conference operator today.

Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.

We have a solid slate of reports today, both of the earnings variety and regarding economic growth.

Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.

During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early stages of a transformation. We sold Madrigal Pharmaceuticals, Inc. to manage risk ahead of a competitor's clinical trial readout.

Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts and improving growth portfolio performance. MS franchise and Alzheimer's therapies face patent expiries, competition, and limited efficacy, pressuring BIIB to deliver new blockbuster products. Growth hinges on pipeline readouts, especially litifilimab in SLE, while subQ Leqembi, Spinraza high dose, Syfovre, and Empaveli are key near-term revenue drivers.

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.